==== OHDSI Transfusion Working Group ==== === MISSION === Extend OMOP CDM and Vocabulary and OHDSI analytic platform to support transfusion research Transfusions are special treatments which are currently in active research by the FDA BEST and the [[https://www.nhlbi.nih.gov/science/recipient-epidemiology-and-donor-evaluation-study-reds-program|REDS-IV]] program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap. == Use Cases == * Effect of number of units on outcomes * Effect of single donor vs pooled on outcomes * Effect agency blood products are obtained from (such as ARC vs NYBC) on outcomes * Incidence rates of severe outcomes: TRALI, TACO, Sepsis, HTRs, PTP, thrombosis and others * Fatality rates of outcomes * Incidence rates of outcomes by specific blood products transfused: red blood cells, plasma, platelets, full blood * Incidence rates of outcomes by blood component processing: leukocyte reduction, irradiation, pathogen-reduction * Incidence rates of outcomes by indication and associated procedures and other possible risk factors * Incidence rates of outcomes by donor characteristics == Modelling Issues == * Detailed facts about transfused units, such as * Manipulation: cultured enrichment, demineralization, genetical modification, * Concentration, dosage, portioning and unit of issue, * Preservation: irradiation and pathogen reduction, transport, storage, cryoprotection, * monitoring: preparation, processing, mobilization, modification, quarantine, * Additive, excipient and nutrient content * Dose * Units * Route * Start/End Time * Multiple touch points of interest (prescribe/dispense/admin) * Lab results specific to the unit for unit-specific data (product CD34+ vs patient CD34+) * [[projects:workgroups:transfusion:members|Participants]] * [[https://forums.ohdsi.org/search?q=transfusion|Forum discussions]] * [[documentation:transfusion:Data_Source|Data Repository]]